MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Pacira Pharmaceuticals Inc-DE

Open

SectorHealthcare

25.21 3.11

Overview

Share price change

24h

Current

Min

24.25

Max

25.19

Key metrics

By Trading Economics

Income

-9.7M

-4.8M

Sales

12M

181M

Profit margin

-2.676

Employees

788

EBITDA

-4.4M

29M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+7.84% upside

Market Stats

By TradingEconomics

Market Cap

76M

1.1B

Previous open

22.1

Previous close

25.21

News Sentiment

By Acuity

50%

50%

149 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Pacira Pharmaceuticals Inc-DE Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 kwi 2025, 23:45 UTC

Hot Stocks

Stocks to Watch: CVS Health, UnitedHealth Group, Spire Global, Pacira BioSciences

Peer Comparison

Price change

Pacira Pharmaceuticals Inc-DE Forecast

Price Target

By TipRanks

7.84% upside

12 Months Forecast

Average 27.25 USD  7.84%

High 30 USD

Low 23 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacira Pharmaceuticals Inc-DE - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

2

Buy

2

Hold

1

Sell

Technical Score

By Trading Central

24.83 / 26.38Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

149 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacira Pharmaceuticals Inc-DE

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
help-icon Live chat